Split Biosciences, now Parse Biosciences, Announces $7M in Series A Funding to Democratize Single Cell RNA Sequencing
Share Article
As adoption of scRNA-seq in industry and academia accelerates, Parse Biosciences (formerly Split Bio) offers the most flexible and scalable single cell sequencing kit, no custom instrument needed
Parse Biosciences
In addition to increased scalability, Parse Biosciences’s technology also provides researchers with higher data quality. Parse enables researchers to increase gene detection in individual cells, while dramatically reducing confounding artifacts that are common in single cell sequencing experiments.
SEATTLE (PRWEB)
January 26, 2021
Split Biosciences, a company providing researchers scalable and flexible single cell sequencing solutions, today announced $7M in Series A funding. The funding round was led by Bioeconomy Capital, an early stage VC firm specializing in companies developing life science tools, with participation from new and existing angel investors. Split Bio also announced a rebrand of the company to Parse Biosciences.